Gilead Files To Break Tamiflu Agreement With Roche, Citing Breach Of Contract
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche will have a chance to address Gilead's claims before their partnership for the flu antiviral is terminated. Gilead claims Roche breached the contract by lessening its marketing efforts, neglecting manufacturing quality management, and inaccurately calculating royalty payments.